Board Updates

5 November 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Board Updates

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces the following changes to the board of directors.

CEO appointment

Rob Baker has been appointed as Chief Executive Officer with immediate effect. Rob has served as the Company's Chief Operating Officer since September 2024 and joined the Board as Senior Executive Director on 28 August 2025. Prior to that, he was Chief of Product and Operations and originally joined the Company as Head of Product in November 2022.

Before joining the Company, Rob held several senior roles at Amazon, including leading large operational teams to scale Alexa voice technology improvements and its privacy and security operations. In addition to his operational expertise, Rob has significant sales and marketing experience having been responsible for regional Amazon Echo device sales, device expansion and large-scale e-commerce programs. Rob began his career at Siemens where he led contract delivery within the Mobility Division before transitioning into regional management roles within the Smart Infrastructure Division.

CFO appointment

Further to the announcement on 28 August 2025, Ronald Openshaw, who has served as Chief Financial Officer and Head of Corporate Development since that date, has been appointed to the Company's Board of Directors with immediate effect. Ronald has served as a consultant to the business advising on strategic matters since 2022 and in August 2024 took over interim leadership of the Company's finance function.

Ronald began his career at KPMG before becoming a senior healthcare investment banker at both Jefferies and Panmure Gordon.  He has served as Chief Executive Officer and/or Chief Financial Officer of several companies including Simbec-Orion, a clinical research organisation, Plethora Solutions, a speciality pharmaceutical company and Pharmagene/Asterand - a pioneer in the use of human tissue in drug discovery and development. He has also advised numerous other companies in the life science and healthcare sector on strategy, operational delivery and acquisitions and disposals.

Appointment of chair designate and future board changes

Further to the announcement that Dr Steven Powell would retire as non-executive Chair of the board at the next annual general meeting the board announces that Mr Nick Rodgers, who joined the Company as a non-executive director in January 2024, will become Chair designate. Nick is an adviser to gene therapy company Santo Therapeutics and was until May 2024, Chair of SEHTA, a health technology membership and networking organisation supporting businesses in the health technology sector. Until 2023 Nick was Chair of Destiny Pharma plc, a developer of novel anti-infective products and chair of ZPN Energy Limited, a developer of battery storage technologies and systems. Previously, until 2016, Nick was chairman of Oxford BioMedica plc, a pioneer of gene and cell therapy.

The Company expects to recruit a new, additional non-executive director to the board and will make further announcements as the process proceeds.

Finally, the Company announces that Mr Alex Livingstone-Learmonth will not as previously planned join the board. Alex has informed the Company that he intends to pursue other career opportunities outside Cambridge Cognition and will leave the company in the new year. Alongside Rob, Alex has transformed the Company's commercial group since his appointment in early 2024 and the Company wishes to thank him for his valuable contribution.

Dr Steven Powell said:

"We are pleased to announce these changes to the Board of directors as the Company continues to advance its growth and development. Following the leadership changes introduced in autumn 2024, Rob has demonstrated strong leadership qualities and we are excited to support his appointment as CEO. Ronald joining the board is a natural and welcome progression having supported the Company for several years. I am pleased that Nick has become Chair designate, bringing his many years of Board expertise and governance knowledge."

FURTHER INFORMATION:

The following additional information is provided in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:

James Ronald Openshaw, aged 59, holds or has held the following directorships in the last five years:

Mr Openshaw was a director of The Urology Company Limited at the time of its creditors' voluntary liquidation on 17 September 2013. Mr Openshaw was declared bankrupt by The Insolvency Service on 26 April 2016. He was subsequently discharged from bankruptcy, a statutory process, on 26 April 2017.

Save for the information disclosed above, there is no other information in relation to Mr Openshaw that is required to be disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AІM Rules for Companies.

Enquiries:

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

· Clinical Studies for new pharmaceuticals;

· Academic Research for scientists to understand CNS disorders;

· Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

· Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com

END